We are delighted to be part of the Steering Group to lead Australia’s Cell and Gene Catalyst.
The Steering Group comprises AusBiotech, Medicines Australia, CSL Behring, Pfizer, Novartis, Therapeutic Innovation Australia, and Cell Therapies. The Catalyst will advance the Regenerative Medicines in Australia: A Strategic Roadmap for the Regenerative Medicines Sector.
Support for the Catalyst is also being provided by the Victorian Government’s Australian Medtech Manufacturing Centre (AMMC).
Cell Therapies Pty Ltd CEO, Peter Giannopoulos, said: “Australia’s Cell & Gene Therapy ecosystem is burgeoning and now is the time for Australia to invest in building sovereign capabilities and capacity, from translation of basic research through to delivery of cutting-edge products to patients. We are delighted to be part of the CGT Catalyst Steering Group and look forward to contributing to the growth of an industry that can do so much for so many patients in need.
Find out more here.
